Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$9.4MCash, Pro Forma
13.9mo Cash Runway
Follow ISPC by emailGet an email when ISPC reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ISPC, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 9, 2026 ·
Financing Entered a $400,000 private placement of 500 Series D Convertible Preferred shares at $800 per share with accredited investors, closing on or about November 6, 2026. Convertible at the greater of 85% of the prior closing price or a $0.1616 floor, with 8% cumulative dividends. Form 8-K · SEC filing
Nov 5, 2026 ·
Deal iSpecimen completed the November 2 acquisition of two AI products from Foldlab AI for $4.5 million: $750,000 cash at closing, up to $1.25 million in milestone payments, and 2,907,977 restricted shares ($2.5 million) subject to a five-year lock-up. Form 8-K · SEC filing · Press release
Nov 2, 2026 ·
Shareholder vote Stockholders approved a reverse stock split at a ratio between 1:10 and 1:100, to be set by the Board, at an adjourned special meeting on October 30, 2026. The vote was 1,152,016 for, 142,944 against and 868 abstaining, with 1,295,828 shares present. Form 8-K · SEC filing
Oct 9, 2026 ·
Shareholder vote Special meeting results: Proposal 1 (Nasdaq 5635(d) approval for pre-funded warrants) and Proposal 3 (approval for future convertible financings at up to 80% discount) were approved. Proposal 4 (Foldlab AI asset acquisition) was approved. Proposal 2 (reverse split) was adjourned to October 30, 2026. Form 8-K · SEC filing
Sep 10, 2026 ·
Listing Nasdaq extended iSpecimen's time to regain compliance with the $2.5 million minimum stockholders' equity rule until November 25, 2026. The company cites a $2.5 million private placement that closed May 11, 2026, and a planned best-efforts public offering of about $5 million. Form 8-K · SEC filing
Sep 4, 2026 ·
Deal iSpecimen agreed to buy AI software, models and related assets from Foldlab AI for $4,500,000: $2,000,000 cash ($750,000 at closing plus two $625,000 milestone payments) and $2,500,000 in common stock held in a five-year escrow. Closing requires stockholder approval. Form 8-K · SEC filing
Aug 31, 2026 ·
Leadership CEO Katharyn Field transitioned out of the role, not over any disagreement, and will continue as an internal advisor. The board appointed Shahin Behroyan as CEO effective immediately under a contractor agreement with a $350,000 annual fee. Form 8-K · SEC filing
Aug 14, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2025 · N/A · Recruiting · Collection and Distribution of Biospecimens for Novel Research Uses Registry date passed, readout not confirmed
💰 Cash Runway & Dilution Risk
ISPC had $4.4M in cash and short-term investments on its Jun 30, 2026 balance sheet.
Including the cash events since then, it holds about $9.4M pro forma, before operating spending after that date:
Closed public offering, announced Aug 7, 2026 (gross proceeds): $5M · 8-K
It burns about $2M/quarter from operations, an estimated runway of 13.9 months from Jun 30, 2026 at that rate (BioRadar estimate, not company guidance).
Dilution pressure:43 · Elevated
Cash runway 14 months (pro forma for cash events since the balance sheet) +18
Shelf registration (S-3, Oct 2025) +10
Going-concern doubt in the latest 10-Q +15These conditions raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year from the date these unaudited condensed financial statements are issued.10-Q, Aug 2026
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ISPC and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.